S
DFTX

SignatureFD’s Definium Therapeutics DFTX Stock Holding History

SignatureFD’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2
Closed -$27 – 3551
2025
Q4 		$27 Hold
2
– – ﹤0.01% 3354
2025
Q3 		$24 Hold
2
– – ﹤0.01% 3349
2025
Q2 		$13 Hold
2
– – ﹤0.01% 3239
2025
Q1 		$12 Hold
2
– – ﹤0.01% 3301
2024
Q4 		$14 Hold
2
– – ﹤0.01% 3282
2024
Q3 		$11 Sell
2
-66
-97% -$459 ﹤0.01% 3220
2024
Q2 		$490 Hold
68
– – ﹤0.01% 2990
2024
Q1 		$639 Hold
68
– – ﹤0.01% 3004
2023
Q4 		$249 Hold
68
– – ﹤0.01% 3040
2023
Q3 		$213 Buy
68
+66
+3,300% +$271 ﹤0.01% 3088
2023
Q2 		$7 Hold
2
– – ﹤0.01% 3219
2023
Q1 		$6 Hold
2
– – ﹤0.01% 3267
2022
Q4 		$4 Sell
2
-2
-50% -$6 ﹤0.01% 3272
2022
Q3 		$0 Buy
4
+2
+100% +$19 ﹤0.01% 3256
2022
Q2 		$0 Hold
2
– – ﹤0.01% 3260
2022
Q1 		$0 Hold
2
– – ﹤0.01% 3257
2021
Q4 		$0 Hold
2
– – ﹤0.01% 3205
2021
Q3 		$0 Hold
2
– – ﹤0.01% 3151
2021
Q2 		$0 Buy
+2
New +$105 ﹤0.01% 3012

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SignatureFD's DFTX Position: Q1 2026 in Review

SignatureFD sold out of Definium Therapeutics (DFTX) in Q1 2026, closing a stake of 2 shares — an estimated $27 sold.

SignatureFD first reported a position in DFTX in Q2 2021 and held it in 19 quarters. The position peaked at $639 in Q1 2024. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • SignatureFD reported no remaining Definium Therapeutics position as of Q1 2026 after selling out during the quarter.
  • SignatureFD sold 2 Definium Therapeutics shares in Q1 2026, an estimated $27.
  • SignatureFD first reported a position in Definium Therapeutics in Q2 2021 and held it in 19 quarters.
  • SignatureFD's Definium Therapeutics position peaked at $639 in Q1 2024.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on SignatureFD's 13F filing for Q1 2026, filed 7 Apr 2026.